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Abstract.
Background: Immersive virtual reality (iVR) allows seamless interaction with simulated environments and is becoming an
established tool in clinical research. It is unclear whether iVR is acceptable to people with Alzheimer’s disease (AD) dementia
or useful in their care. We explore whether iVR is a viable research tool that may aid the detection and treatment of AD.
Objectives: This review examines the use of iVR in people with AD or mild cognitive impairment (MCI).
Methods: Medline, PsycINFO, Embase, CINAHL, and Web of Science databases were searched from inception. PRISMA
guidelines were used with studies selected by at least two researchers.
Results: Nine studies were eligible for inclusion. None reported any issues with iVR tolerability in participants with MCI
and AD on assessment or treatment tasks. One study demonstrated capability for detecting prodromal AD and correlated
with neuroanatomical substrates. Two studies showed iVR to have high accuracy in differentiating participants with AD from
controls but were not hypothesis driven or with adequate controls measures. In a small validation study and two longitudinal
case studies, iVR cognitive training was positively rated but did not demonstrate reliable benefit.
Conclusion: iVR is emerging as a viable method of assessing older adults and people with AD. Strongest benefits were seen
when closely integrated with theoretical models of neurodegeneration and existing screening methods. Further randomized
controlled trials integrated with clinical populations are required. This will consolidate the power of iVR for assessment of
MCI and clarify treatment efficacy beyond current applications in physical rehabilitation.
Keywords: Alzheimer’s disease, cognitive remediation, mild cognitive impairment, spatial navigation, virtual reality
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INTRODUCTION
In this systematic review, we investigate the use of
immersive virtual reality (iVR) technology in stud-
ies aiming to improve the diagnosis or treatment
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of Alzheimer’s disease (AD). New approaches are
sought due to the high societal burden of AD com-
bined with a lack of effective treatments. There is
hope that supporting vulnerable people early may
help prevent disease progression at or before the onset
of mild cognitive impairment (MCI) [1]. iVR has
already demonstrated advantages in the treatment of
mental health conditions from anxiety disorders to
psychosis [2]. iVR has been utilized in public aware-
ness campaigns allowing users to take a ‘walk through
dementia’ [3] and reminiscence activities allowing
experiences to be shared with family [4]. These appli-
cations have an intuitive appeal but it remains unclear
whether iVR can aid the diagnosis or treatment of AD
dementia.
Virtual reality uses computer simulation to replace
an individual’s external sensory world with an arti-
ficial environment that updates corresponding to
an individual’s orientation and physical movement.
Early virtual reality equipment was limited in its
ability to create naturalistic interaction. Artificial
environments were reliant on 2D displays and con-
trollers such as joysticks and mouse devices which
require practice for effective use (Picture 1). By con-
trast iVR uses head mounted displays (HMD) which
adjust the input to each eye to create a true sense
of perspective in 3D (Picture 2). Interaction is more
naturalistic using head/hand movements or walking
within a monitored field. Controllers are incorporated
into the simulation, and joystick use is less common.
We define ‘immersive’ virtual reality as systems that
encompass the user’s visual field and where virtual
movement replicates actual head or bodily move-
ment.
HMDs achieve immersion by excluding exter-
nal visual input and updating the simulated visual
environment in relation to head movements. This
helps integrate vestibular, proprioceptive, and visual
information. These sensory cues enable a more accu-
rate representation of position [5] and are scarcely
recruited during non-immersive VR paradigms. Col-
lectively such cues contribute to an experience that
is not only immersive but intuitive—participants do
not need to be shown how to move, they just move.
HMD systems are also rapidly dropping in price and
are already affordable to individuals, clinics, and care
homes.
iVR can also be achieved using Cave Automatic
Virtual environments (CAVE systems, Picture 3).
CAVE systems use a combination of video display
walls, motion capture systems, and stereoscopic LCD
shutter glasses to simulate a 3D world. An advantage
of CAVE systems is their ability to allow interaction
with real world objects in a projected virtual world;
however, these come at a greater cost than HMD-
mediated iVR and require specialized and dedicated
rooms.
Early iVR systems suffered lag in visual updat-
ing that led to mismatch between visual perception
and vestibular feedback (e.g., head rotation or walk-
ing) that commonly induced nausea in participants
[6]. Modern iVR technology overcomes these issues
through a 1 : 1 correspondence of movement to
visual perception; however, this has not yet been
systematically appraised in a patient population.
Other important technical issues in need of clarifi-
cation include how well people with AD and MCI
tolerate HMD equipment and whether individual
differences in sensory impairment affects use of
equipment.
iVR allows for naturalistic interaction with a sim-
ulated world which could potentially offer accurate
discrimination of AD pathology on spatial cognitive
tasks [7]. Unlike episodic memory, isolated impair-
ments in spatial navigation are specific to early AD [8]
and otherwise silent hippocampal strokes [9]. These
impairments are not observed in aging, depression,
or other neurodegenerative diseases. Tasks of spa-
tial cognition may therefore offer earlier detection of
AD ahead of current gold standard episodic mem-
ory measures. Immersive environments are critical
for such spatial tasks that are dependent on medial
temporal lobe structures; the primary site of neurode-
generation in AD [10–14]. iVR suits this purpose well
through use of large landscapes that would not be
possible with other techniques. While the utility of
iVR is exemplified by spatial cognitive paradigms,
this review examines the wider application of iVR to
potential diagnostic and therapeutic applications that
may benefit AD.
Previous reviews have looked at the use of vir-
tual reality in diagnostic assessment of AD using
a mixture of spatial cognition; task sequencing and
episodic memory with no clear differential bene-
fit noted compared to existing techniques [15–17].
However, these paradigms were not immersive and
used deprecated technology. As a result, the validity,
tolerability, and possible diagnostic utility of immer-
sive tasks for AD remains unclear. It is also unclear
whether iVR can be used for people with MCI to
predict progression to AD or whether it might be
sensitive to neurodegeneration before significant cog-
nitive decline has occurred. In this review we address
these issues.
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Broader reviews of computer-based interventions
for AD treatment have noted that non-immersive vir-
tual experiences are enjoyed by participants, reduced
apathy, and were preferred when compared to non-
virtual experiences [18, 19]. Early reviews found
very weak evidence that iVR was more effective than
conventional virtual reality for cognitive training in
people with a range of neurodegenerative conditions
but did not use robust definitions of iVR or dementia
subtypes meaning that it is harder to make conclu-
sions about clinical applicability [20]. Kim et al.’s
recent meta-analysis suggests modest effects of semi
immersive VR treatment across a range of outcomes
from physical fitness, cognition, and emotion but used
an incomplete definition of iVR by suggesting use
of a 3D display as sole criteria [21]. In both cases
there was a risk of relevant studies being either missed
or misclassified as immersive. Other recent reviews
have looked much more broadly at treatment of neu-
rocognitive disorders but did not look at specific
applications in AD [22].
As a result, it remains unknown if iVR cogni-
tive training or stimulation tasks lead to functional
improvements in AD, benefit other important
symptoms such as mood or wellbeing [23], or facil-
itate engagement in activities which provide other
therapeutic benefit. Such activities might include
physiotherapy or occupational therapy rehabilitation
which could otherwise be difficult to access for
patients with AD. No previous reviews have consid-
ered this area. In this review we included all treatment
studies. While previous reviews of the field have
produced a number of interesting observations, the
current study sought to examine, extend, and refine
these insights in two key ways. First, we emphasize
the importance of a precise and consistent definition
of iVR. Second, we focus entirely on AD rather than
neurocognitive disorders more broadly.
It also remains unclear how well people with MCI
or AD tolerate the experience of iVR. A previous
review suggested people with AD suffer increased
anxiety around virtual reality but this was not using
an iVR application [24], whereas another study found
that participants preferred an iVR-mediated cogni-
tive assessment over pen-and-paper tests as it was
more intuitive [25]. Evidence from managing behav-
ioral disturbance in institutional settings has also
demonstrated that even in these challenging settings
iVR can be well tolerated and even enjoyed [24,
26]. In this review we explore this issue by apprais-
ing both quantitative and qualitative measures of
acceptability.
In summary, iVR offers a novel and ecologi-
cally valid opportunity for diagnostic assessment
and therapeutic intervention that may have unfore-
seen potential in AD. Given the prevailing emphasis
on earlier diagnosis, cognitive-behavioral paradigms
developed to target neuroanatomical sites com-
promised early in AD are vital. However, such
assessments (e.g., navigation) have been overlooked
by previous reviews, potentially owing to difficulty in
application and replication. iVR paradigms overcome
these limitations but the clinical benefit, acceptabil-
ity, and engagement with this technology in AD and
MCI has not been adequately reviewed. In this review
we address these issues.
METHOD
Systematic literature review
A systematic literature review was conducted using
the databases PubMed, Embase, Cinahl, PsycINFO,
the Cochrane Library, and the Web of Science
Core Collection. A protocol was developed based
on the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) statement
[27]. Details of the protocol for this systematic review
were registered on the PROSPERO database [28]
under registration number CRD42018115173.
Search strategies
The databases were searched from inception up to
July 26, 2019. Key phrases were determined in con-
junction with an experienced research librarian (Isla
Kuhn, IK) with the search terms optimized for each
database. The search strategy was refined through
comparison to the Cochrane review of virtual reality
use with people who have suffered strokes [29].
Key terms are listed below and a copy of the
full search strategy is available from the authors
on request. Search items (also heading searches)
included: ‘Virtual Realit*’ OR ‘VR’ OR ‘computer
AND (simulation* OR generat* OR therap* OR
treatment*)’ AND ‘Alzheimer*’
Eligibility criteria
Articles were accepted in all languages. No restric-
tions were set with regard to study type or the
publication date.
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Inclusion:
• Participants: Must include participants with AD
or MCI at high risk of developing into AD (e.g.,
amnestic presentation/ biomarker positive).
• Intervention: Use of an immersive 3D virtual
reality paradigm, e.g., 3D head mounted display
or CAVE system
• Control: Nil specific criteria
• Outcome: Any study design including quantita-
tive or qualitative outcomes based on individual
data.
Exclusion:
• Participants: Study ONLY includes healthy con-
trols/participants with other non-dementia or
other dementia conditions, e.g., Lewy body
dementia.
• Intervention: No virtual reality or non-
immersive virtual reality used, e.g., 2D tablet/
conventional computer screen display.
• Control: Nil specific criteria.
• Outcome: Reviews/technology appraisals.
Selection process
• Step 1: Search results were uploaded into
Rayyan Online Systematic Review Management
Software [30] for initial screening. Duplicates
were removed.
• Step 2: Title/abstract screening: The remaining
titles and abstracts were screened independently
by two team members (FC and JF) to identify
studies that potentially met the inclusion criteria.
If no abstract was available, additional informa-
tion was searched manually on the internet to aid
the selection process. Relevant review articles
were retained for manual screening if they poten-
tially referred to studies which met the eligibility
criteria. A third author (AP) resolved disputes.
Reasons for exclusion were noted.
• Step 3: Manual screening of review articles:
The references and full text of retained review
articles were searched independently by two
members of the team (FC and JF) for additional
relevant studies. Duplicates were removed.
• Step 4: Full text eligibility review: The full text
of the remaining studies was assessed for eligi-
bility independently by two team members (FC
and DH). A third author (AP) resolved disputes.
References of retained studies were searched
for additional relevant studies which were then
assessed for eligibility. Reasons for exclusion
were noted.
• Step 5: Final screening during data extraction:
Detailed analysis of papers for data extraction
included final review of eligibility for inclusion.
Data extraction and quality assessment
A data extraction form for the included studies
was developed in Windows Office Excel 2010, based
on the Cochrane Handbook for Systematic Reviews
[31]. The data extraction form used is available from
the authors upon request: We included:
• Data about the publication: Authors, title of the
article/journal, year of publication.
• Method
• Study design, setting, diagnosis and severity of
dementia, comorbidities
• Description of the VR assessment/intervention
and control, number of participants in
the VR assessment/intervention and con-
trol/comparison group. For treatment studies:
including how many were randomized and
how many analyzed (with reasons for drop
out), duration of the trial (incl. duration of the
intervention and timing of follow up).
• Outcome measures, type of analysis
• Results
• Outcome data for patients with AD/high risk
MCI was compared to controls including other
neurodegenerative conditions.
• For assessment studies: between groups (VR
versus control condition) effects: p-values &
effect sizes (95% CI, Cohen’s d).
• For treatment studies: baseline and follow up(s),
between groups (VR versus control condition)
effects:p-values & effect sizes (95% CI, Cohen’s
d).
• Summary of the study conclusion.
We noted whether the authors needed to be con-
tacted for any additional information and if so, which
specific information was required. Three reviewers
(FC, JF, DH) extracted the data independently. Any
disagreement between the reviewers was resolved
through discussion with a fourth reviewer (AP). If rel-
evant information could not be found in the included
studies, the authors were requested to provide the
missing information if possible.
Two reviewers independently (FC and DH)
assessed the risk of bias of the included studies.
This was based on the Cochrane Collaboration’s tool
for assessing risk of bias which includes selection
bias, performance bias, detection bias, attrition bias,
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reporting bias, and any other potential sources of bias
[32]. We also used the ROBINS-I tool for assess-
ing risk of bias in non-randomized trials where this
was more suitable [33]. Any disagreements between
the two review team members about the risk of bias
assessment was resolved through discussion with a
third review team member (AP) if necessary. DH
was not involved with any data extraction or criti-
cal appraisal of the study by Howett et al. [34] due to
his involvement with this study as primary author.
RESULTS
Study selection
The selection process is summarized according to
PRISMA guidelines [27] in Fig. 1 as a flow chart.
The initial search strategy yielded 7,805 results from
the selected databases, comprising 2,869 records
from Medline via OVID, 1,351 records from Embase
via OVID, 736 records from PsycINFO via Ebsco,
136 records from CINAHL via Ebsco, 208 records
from Cochrane, and 2,505 records from Web of
Science.
After removal of duplicates, 5,823 records were
screened by two authors based on title, abstract, and,
if applicable, additional information. Disagreements
about in- or exclusion of 118 studies were resolved
by a team of three authors. In this first stage, 5,731
records were excluded for the following primary rea-
sons: 5,574 wrong intervention (i.e., not immersive
VR study), 157 wrong participants (i.e., not including
participants with probable or possible AD/MCI).
The full text was retrieved of the remaining articles
(n = 92) and of relevant reviews (n = 41). References
of these articles were screened. This led to 5 records
being added for full text screening. Further details of
3 conference posters were not available but authors
were contacted where possible to obtain details of
subsequent publications.
The remaining 97 articles were read in full text and
assessed against eligibility criteria by two authors. 88
were excluded leaving a total of 9 studies included
in this review (5 assessment studies, 4 treatment
studies). Meta-analysis was not possible due to het-
erogeneity of study designs, intervention contents,
outcomes measured, and clinical groups sampled.
Assessment studies
The five eligible studies are summarized
below. Full details are shown in Table 1a:
Fig. 1. PRISMA Diagram.
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Table 1a
Design and Aims of Assessment Studies
Study Design/aims Setting/ Diagnosis/ VR technology/ Outcome Comparison task
participants comorbidities task measures
Fernandez-
Montenegro et
al. [35]
Validation Study
(Repeated
Measures): To
compare novel
VR screening
tests of AD to
traditional pen
and paper tests
Computer
Sciences
Department,
Kingston
University, UK
N = 20 aged
23–82, healthy
controls and
patients (no
details on
proportion), 11
female, 11 high
school
education or
higher.
Nationalities
included
French,
Spanish,
Vietnamese and
Greek, one
participant was
illiterate.
AD, No details
given of criteria
or number of
patients/
comorbidities
Oculus Rift DK2
HMD with
Microsoft
Kinect 2 depth
sensor.
Participant is sat
in a simulated
consulting room
to complete
tasks:
Remembering
object loca-
tions/noticing
scene changes
and sound
location. No
information on
software used.
Four tasks
measuring
visual memory,
auditory
recognition, and
discrimination
Dr. Oz Memory
Quiz; Visual
Association
Test, Dichotic
Listening Test
Gago et al. [36] Case Control: To
explore
differences in
provoked
compensatory
postural
adjustments
within an VR
environment in
patients with
AD who had
suffered falls in
the past 12
months
(‘fallers’) to
‘non-fallers’
and controls
Neurology
Department,
Guimaraes,
Portugal.
N = 21 patients
recruited from
local memory
clinic.
–11 ‘fallers’ 9
female, mean
age 71, average
1-4 years
education, mean
disease 3 years,
mean MoCA
score 9.
–9 ‘non-fallers’
5 females, mean
age 75, average
1-4 years
education, mean
disease duration
3 years, mean
MoCA score 12
N = 19 healthy
controls (from
previous study).
11 females,
mean age 71,
average 1-4
years of
education, mean
MoCA score 24
AD, DSM-
IV/NINCDS-
ADRA,
Comorbidities
not noted.
Exclusion:
orthopedic,
musculoskele-
tal, and
vestibular
disorder,
significant
auditory deficit,
and alcohol
abuse, and
somatosensory
deficit.
Oculus Rift HMD
using Generic
‘Tuscany
scene’.
Participants
identify objects
then stand still
on a virtual stair
case as
unpredictable
visual
displacements
are made.
Compensatory
postural
adjustment
measured by
vertical
acceleration and
time frequency
distribution
Not used
(Continued)
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Table 1a
(Continued)
Study Design/aims Setting/ Diagnosis/ VR technology/ Outcome Comparison task
participants comorbidities task measures
Seo et al. [37] Validation study
(Repeated
Measures): To
explore the
validity and
discriminative
power of a
virtual daily
living test as a
new diagnostic
approach to
assess MCI
Department of
Neurology and
Department of
Engineering,
Hanyang
University
Hospital, South
Korea.
N = 20 patients
(8 female),
recruited from
tertiary medical
center.
N = 22 healthy
controls (8
female)
recruited from
same medical
center.
MCI, Albert
(2011) criteria,
Comorbidities
not stated.
Exclusion:
psychiatric or
neurological
illness,
drug/alcohol
abuse within 4
weeks of the
study.
CAVE system
with 4´2.5´2.5 m
room, four rear
projection
screens,
stereoscopic
glasses to give
3D vision and
Optitrack
motion tracking.
IADL tasks
performed
‘Withdraw
money from
ATM’; ‘Take a
bus’
Kinematic data
collected during
through motion
tracking sensors
(hands and
head). Distance
of sensors, time
taken (whole
task) and
velocity of
movement and
number of
errors: broken
sequence,
misremember
information,
e.g., pin code or
incorrect bus
information.
MMSE, IADL,
FCSRT, Digit
span forwards
and backwards,
2*trail making
tasks.
Zakzanis et al.
[38]
Case Control: To
examine age-
and AD-related
differences in
route learning
and memory
using VR
Psychology
Department,
University of
Toronto,
Canada.
N = 2 patients
(mean age 70).
N = 9 young
controls (mean
age = 26)
N = 7 older
controls (mean
age 62). All
highly educated,
similar
computer use
difference
gaming exp
Probable AD
(NINCDS-
ADRA).
Comorbidities
not stated.
Proview XL-50
HMD with LCD
display and
movement
controlled using
data glove.
Navigation of
specified routes
around
simulated town
of Sunnybrook.
Completion time,
distance
travelled, wrong
turns, ‘falls off
sidewalk’,
collisions with
objects
Not used.
Howett et al. [34] Case Control: To
test the
hypothesis that
entorhinal
cortex-based
navigation is
impaired in
pre-dementia
AD.
Cambridge
University
Hospitals
Memory Clinic,
Cambridge, UK
N = 45 patients
with MCI (26
AD biomarker
tested: 12
positive, 14
negative)
N = 41 controls
recruited from
‘Join Dementia
Research’
group. Age,
gender, and
education
matched.
MCI (Petersen
criteria.
Exclusion:
Patients with
major medical,
psychiatric,
visual, mobility
impairment, or
history of
alcohol
dependency.
HTC Vive iVR
equipment with
external base
stations used to
monitor
participants
within a 3.5 m3
space.
Path integration
task within a
virtual open
area.
Participants
walk a route and
then return to
their base.
Absolute distance
error;
proportional
angular and
linear errors.
ACE-R, NART,
measures
sensitive to
transition from
MCI to AD
(FCSRT, Rey
figure recall,
trail Making
Task, Digit
Symbol test,
4MT)
4MT, 4 Mountains Test; ACE-R, Addenbrooke’s Cognitive Examination Revised; AD, Alzheimer’s disease; DSM-IV, Diagnostic and
Statistical Manual of Mental Disorders IV; FCSRT, Free and Cued Selective Reminding Test; HMD, head mounted display; IADL, instru-
mental activities of daily living; iVR, immersive virtual reality; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination;
MoCA, Montreal Cognitive Assessment; NART, National Adult Reading Test; NINCDS-ADRA, National Institute of Neurological and
Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association; VR, virtual reality.
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Design/background; Table 2a: Outcome measures
and acceptability; Table 3: Risk of bias.
Fernandez-Montenegro et al. [35]
This validation study compared four novel iVR
tasks with existing AD screening measures with the
aim of demonstrating potential alternative screening
measures. A mixture of healthy controls and partic-
ipants with AD completed static iVR object recall
tasks in an HMD setting with joystick control (total
n = 20). All iVR and existing screening tasks were
able to discriminate participants with AD from con-
trols (p < 0.001 for all tasks). Results were potentially
confounded by both age and education level. There
was high correlation between three out of four of the
novel VR tasks and existing measures. There was no
comparison between groups and overall risk of bias
was noted to be high. There was no specific data on
acceptability. Some patients with ‘advanced’ AD did
not complete testing.
Gago et al. [36]
This case control study used a generic scene from
the Oculus Rift HMD catalogue to measure postu-
ral stability in an iVR task for participants with AD
whom had suffered recent falls with those whom had
not (n = 11, n = 9) and matched controls (n = 19). Non
parametric statistics showed that AD fallers made
higher frequency postural adjustments at all time peri-
ods (p < 0.05) with both AD fallers and non-fallers
also showing slower response times to visual pertur-
bations compared to controls. Risk of bias around the
design was high but results and analyses were less
problematic. There was no specific data on accept-
ability. All participants completed all sessions.
Seo et al. [37]
This validation study compared participants with
MCI (n = 20) to healthy controls (n = 22) during an
iVR task in which participants completed instru-
mental activities of daily living (IADLs) in a CAVE
system. Performance was compared to standard neu-
ropsychology measures with the aim of finding
tasks which contributed additional discriminative
value between groups. Results showed significant
differences between participants and controls of
hand speed on a cash machine task (p < 0.005) and
head speed and errors on the catching a bus task
(p < 0.005, p < 0.001). These corresponded to large
effect sizes (1.1, 1.5). There were also significant
between group differences on existing neuropsychol-
ogy assessments. This study was noted to be of high
methodological quality with little risk of bias. There
was no specific data on acceptability. All participants
completed all sessions.
Zakzanis et al. [38]
This case control study compared navigational
abilities of young controls (n = 9) and older controls
(n = 7) with a subset of two participants with AD
on an iVR spatial navigation task using HMD and
a joystick. There was no control task. Performance
on navigation tasks was varied for the two partici-
pants with AD; one markedly impaired on all tasks,
the other within 1 standard deviation of controls for
all tasks. There was no between group comparison
made which included participants with AD. There
was no specific data on acceptability. All participants
completed all sessions.
Howett et al. [34]
This case control study compared performance of
participants with MCI (n = 45) to matched controls
(n = 41) during an iVR path integration task designed
to test entorhinal cortex function. A proportion of
participants with MCI were tested for cerebrospinal
fluid biomarkers of AD (amyloid- 1–42, total tau,
phosphorylated tau, n = 26, 12 positive, 14 negative).
A proportion of test subjects also completed MRI
measures of entorhinal cortex volume (39 partici-
pants with MCI: 11 biomarker positive, 9 biomarker
negative, 37 controls). Participants with MCI who
had cerebrospinal fluid biomarkers positive for AD
showed significantly impaired path integration per-
formance compared to participants with MCI with
negative biomarkers and controls whose performance
did not significantly differ. The path integration task
showed significantly higher diagnostic sensitivity and
specificity for differentiating biomarker positive ver-
sus negative MCI compared to the best of current gold
standard cognitive tests (area under the curve 0.90
versus 0.57). Entorhinal cortex volume on MRI was
negatively associated with errors on the path integra-
tion task (p < 0.005). This study was at low risk of bias
with good methodological quality. There was no spe-
cific data on acceptability. All participants completed
all sessions.
Treatment studies
The four eligible studies are summarized
below. Full details are shown in Table 1b:
Design/background; Table 2b: Outcome measures
and acceptability; Table 3: Risk of bias.
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Table 1b
Design and Aims of Treatment Studies
Study Design/aims Setting/ Diagnosis/ VR technology/ Outcome Comparison task
participants comorbidities task measures
Bourellier et al.
[39]
Validation study
(Repeated
measures): To
assess the use of
a VR training
environment to
Engage Motor
and Postural
Abilities.
Department of
Geriatrics,
University of
Bourgogne,
France.
N = 7 patients,
average MMSE
23.2, Average
timed up and go
test 13.3 s
N = 14, controls
matched for
age/gender,
average MMSE
28.5, Average
timed up and go
test 9.5 secs
MCI, NINCDS-
ADRDA
criteria;
comorbidities
not mentioned,
all nor-
mal/corrected
normal hearing
and vision
CAVE System
with dimensions
3.40 m3, 3D
vision via
NVidia 3D
Vision Pro
stereoscopic
glasses and
ART DTrack
2motion
tracking.
Simulated fruit
harvesting task
designed to
induce
stretching: fruit
in from different
start positions
are selected for
ripeness and
placed in a
basket. 6*
3-min sessions
with 1-min
break between
each session.
Number of
appropriate
movements:
Ripe fruit
picked on
implicit VR task
versus targeted
movement on
explicit exercise
task.
Explicit exercise
task: Arm
pointing task
with
physiotherapist.
White and
Moussavi.
[40]
Case study: To
determine
whether an
individual with
AD could learn
to navigate in a
simple VR
navigation
environment
Department of
Biomedical
Engineering,
University of
Manitoba,
Canada.
N = 1,
74-year-old
male, masters
level education,
MoCA 24/30
MCI, probable
AD (no criteria
given),
comorbidities
not mentioned.
Oculus Rift DK2
HMD:
Participant is
shown a room
on the outside
of a building
and asked to
navigate to it.
45-min training
sessions,
3*week for 7
consecutive
weeks (total
16 h)
Navigation errors,
serial MoCA
score.
Not used.
Optale et al. [41] Case study: To
explore whether
cognitive
processes could
be restored via
procedures
practiced
repetitively
within an
environment
which contains
functional
real-world
demands
Department of
Neuro-
Rehabilitation,
Villa Salus
Hospital,
Venice, Italy.
N = 1 Patient
from memory
clinic, female,
aged 65, high
school
education.
Early onset AD
(no criteria
given). Full
details of all
comorbidities
mentioned. No
family history
of dementia.
Virtual Research
System HMD
with Intersense
motion tracker
and Joystick
control.
Three listening
experiences
alternated with
three different
virtual
experiences
using
Superscape
VRT software:
re-experience of
childhood,
Subjective
measures of
improvement,
Multiple
Delayed
Reaction Ver-
bochronometry
and Neuropsy-
chology
measures
(MMSE,
Wechsler
Memory Scale,
Digit span,
Praxia Tests,
Frontal Lobe
measures
Not used.
(Continued)
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Table 1b
Continued)
Study Design/aims Setting/ Diagnosis/ VR technology/ Outcome Comparison task
participants comorbidities task measures
participating in
a tournament,
and walking the
streets of a
modern city.
Tasks gradually
more complex.
15 min, 3* week
for 12 weeks,
then reduced to
3*weekly
sessions every
two weeks for a
further 12
weeks (13. 5 h
total).
(towers of
Hanoi, Stroop
test),
Visual-spatial
Tests Cubes,
Global
Deterioration
Scale) at
baseline, 5, 8,
and 12 months
Micarelli et al.
[42]
Case Control:
Explore the
effect of a head
motion-
dependent VR
racing game on
vestibular
rehabilitation in
UVH patients
encompassing
MCI and
cognitively
unimpaired
older adults.
ITER Center for
Balance and
Rehabilitation
Research,
Rome, Italy.
N = 24 patients
with MCI (mean
age 74.4, 14
females, mean
MMSE 25.5)
N = 23 controls
(mean age 75.6,
12 females,
mean MMSE
28.1)
MCI diagnosis
according to
Albert criteria
(2011). Chronic
UVH diagnosed
by a 25%
reduction in
vestibular
response to
bithermal water
caloric
irrigation on one
side 3 months
after the
beginning of
symptoms.
Exclusion:
Significant
medical
disorders.
VR Tech: 5.2”
display of a
Windows Phone
placed in the
HMD
‘Revelation’ VR
Headset.
Trackspeed 3D
racing game
20 min per day:
point of view
never ending
racing race in
which the car is
steered from the
cockpit by
tilting the head
Otoneurological
testing: Head
impulse testing,
Postuography.
Self-report:
Dizziness
Handicap
Inventory,
activities-
specific balance
confidence
scale, dynamic
gait index.
Simulator
sickness
Questionnaire,
nausea
oculomotor
stress, and
disorientation.
Vestibular
rehabilitation
only, twice daily
30–40 min in
total.
UVH, unilateral vestibular hypofunction. See Table 1A for remaining abbreviations.
Bourellier et al. [39]
This validation study assessed the use of an
iVR training environment for participants with MCI
(n = 7) versus matched controls (n = 14) in compari-
son to a usual physiotherapy task. The iVR task used
a CAVE system object sorting task which required
large movements of the body, this was compared to
a standard physiotherapy session practicing similar
movements over a single session. Results showed a
strong difference in appropriate movements between
both MCI participants versus controls and iVR versus
conventional physiotherapy (both p < 0.001). There
was also a strong interaction: participants with MCI
were proportionately worse than controls on the iVR
task in particular. There was a between groups differ-
ences on Mini-Mental State Examination (MMSE)
and timed up and go task (TUG) which was con-
trolled for during statistical analysis. This study was
at low risk of bias with good methodological qual-
ity. Acceptability of the technology was explored in
detail through a 30-min semi structured interview:
participants reported enjoying the iVR training more
than the standard physiotherapy sessions which they
found repetitive.
White and Moussavi [40]
This case study with a single participant looked at
whether a patient with AD could engage with and
learn from an iVR navigation program completed
using HMD and innovative wheel chair control. No
details were given about diagnostic criteria used.
There was no control task. Training was completed
three times a week over 7 weeks. Results showed
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Table 2a
Results of Assessment Studies
Study Between groups Outcome Acceptability Effect sizes Subjective
differences measures measures
Fernandez-
Montenegro et
al. [35]
No comparison
made between
groups based on
demographic
measures.
Parametric statistics used to
compare groups (Dementia
versus controls, table 4):
Significant difference noted
between groups for all
neuropsychology and novel
measures (all p < 0.001).
Also, significant
differences between age
and DrOz test (p = 0.033),
DLT (p = 0.038), and novel
object recognition task
(p = 0.003). Significant
differences also between
level of education and three
of the novel tasks VOM
(p = 0.045), AOR
(p = 0.004), BDTT
(p = 0.0).
Correlation between novel
and existing measures
• VOM (t = 0.59-0.83,
p < 0.01 for all measures)
• AOR (t = 0.53-0.74, p < 0.01
for all measures except
VAT p = 0.017)
• VRS (t = 0.49-0.72, p < 0.01
for all measures except
DrOz p = 0.03)
• BDTT: Not significantly
correlated with any existing
measure.
No specific data.
Some patients
with ‘advanced’
AD did not
complete all
sessions.
No data to allow
this.
Positive feedback
on VR headset,
instructions and
movement
interaction, no
statistics.
Gago et al. [36] Nil significant
differences
demographic
and
anthropometric
measures;
significantly
lower score on
MoCA for both
dementia groups
versus controls
(Kruskall Wallis
Tests, p < 0.001
further details
given).
Vertical acceleration
Significant difference
between controls and AD
fallers (higher mean,
U = 38.0 p = 0.03; higher
average magnitude
(U = 53.0, p = 0.026)).
Movement power: Intergroup
analysis
• Significant difference
between AD fallers to
controls for all time periods
(p < 0.05)
• No significant differences in
low band (<1.5 Hz)
movements between other
groups (p ranges 0.26-0.56)
• Significantly higher value
of high band (>1.5 Hz)
compensatory adjustments
for AD fallers versus
controls at all times (table
2, p < 0.05 for all
comparisons).
No specific data.
All participants
completed all
sessions.
Not calculated. Not used.
(Continued)
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Table 2a
(Continued)
Study Between groups Outcome Acceptability Effect sizes Subjective
differences measures measures
Movement power: Intragroup
analysis
• Controls increased power
immediately after
perturbation (0-4 s) versus
before (-4-0 s, p = 0.002)
and at delay (4-8 s,
p = 0.01)
• Both AD faller and
non-faller groups showed
increased power after a
delayed period (0-4 versus
4-8 s, p = 0.005 and
p = 0.20)
Seo et al. [37] Nil significant
difference
between groups
based on gender
or
demographics/
depression scale
(Table 1).
There were
significant
differences
between groups
on some of the
cognitive
assessments on
MANOVA
• MMSE, F = 7.9,
p = 0.007,
• Immediate
recall, F = 22.1,
p < 0.001
• Delayed recall,
F = 7.4,
p = 0.009
• Digit span
backwards,
F = 7.7,
p = 0.009
• Trail making
task A time,
F = 4.4,
p = 0.043
VDLT compared between
MCI and controls
MANOVA (F (8,33)=5.6,
p < 0.001)àunivariate
analysis with Bonferroni
correction showed
significant results for Hand
speed on task 1 (p = 0.001),
slower head speed and
more errors on task 2,
p = 0.002, p < 0.001).
Correlation with
neuropsychology tests
Hand speed in task 1 and head
speed in task 2 did not
correlate with neuro psych
measures but number of
errors was inversely
correlated.
Discriminating performance
Compared using
neuropsychology measure
(immediate free recall) and
two non-correlated but
discriminating kinematic
measures (hand/ head
speed); Wilks Lambda
showed significant changes
as each was added with
eventual accuracy 92.9%,
sensitivity 90%, specificity
95.5%
No specific data.
All participants
completed all
sessions.
Hand speed on
task 1 : 1
Head speed on
task 2 : 1
Number of errors
on task 2 : 1.5
Not used.
Zakzanis et al.
[38]
No data on
patients.
Young versus old
controls:
• No difference in
education
level/years of
computer use
(p = 0.09,
p = 0.89).
No comparative statistics for
the two patients versus
controls.
Neuropsychology measures
• Patient JH was marked
impairment on verbal tasks
versus performance;
• Patient SD more impaired
on recall tasks.
Spatial navigation in VR
Patients with AD
did not
complete the
cybersickness
questionnaire.
No specific data.
All participants
completed all
sessions.
Not applicable No data on
patients.
Cybersickness
measures for
controls showed
significant
increase during
versus after
immersion
(r = 0.65,
p = 0.01)
(Continued)
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Table 2a
(Continued)
Study Between groups Outcome Acceptability Effect sizes Subjective
differences measures measures
• Significant
difference in
years of
experience with
video
games/age
(p < 0.05,
p < 0.01).
• JH: performance was within
one standard deviation of
older controls for all tasks
• SD: more than 2-3 standard
deviations worse for all
tasks.
Howett et al. [34] • Nil significant
differences age,
gender,
educational
level.
• Significant
difference in
ACE-R
(p < 0.05) and
other cognitive
assessments
between
controls and
patients with
MCI (p < 0.05)
Absolute distance error
increased for patients with
MCI compared to controls
(57.33 cm, t(1, 107)=3.24,
p < 0.01). Increased errors
for biomarker positive
patients versus biomarker
negative patients (97.56 cm,
t, 163, 4.69, p < 0.001).
Lower ACE-R scores
correlated with greater
distance errors
(t(1,85)=2.89, p < 0.01).
Significant negative
associations between
absolute distance error and
total entorhinal cortex
volume on MRI
(F(1,64)=9.60, p < 0.005).
Area under the curve for
absolute distance error
MCI biomarker+ve versus
–ve 0.9 (CI 05.9-1)
compared to ACE-R (0.53,
CI 0.24-0.73) and other
cognitive assessments (e.g.,
Trail making task B, 0.57,
0.22-0.69, 4MT 0.56, CI
02.-0.72).
No specific data.
All participants
completed all
sessions.
Not applicable Not used.
4MT, 4 Mountains Test; ACE-R, Addenbrooke’s Cognitive Examination Revised; AD, Alzheimer’s disease; AOR, Abnormal Objects
Recognition Test; BDTT, Bot Doctor Turing Test; DLT, Dichotic Listening Test; MANOVA, multivariate analysis of variance; MCI, mild
cognitive impairment; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; MRI, magnetic resonance imaging;
VAT, Visual Association Test; VDLT, Virtual Daily Living Test; VOM, Virtual Objects Memorization; VR, virtual reality; VRS, Virtual vs.
Real Sounds
that neuropsychology scores remained stable over a
28-week period following treatment. Their partici-
pant showed sustained learning on the navigation
task. Subjective improvements were noted including
a reduction in self-deprecating comments. There was
no specific data on acceptability.
Optale et al. [41]
This case study with a single participant with
AD monitored the effect of practice of functional
real-world tasks in iVR using HMD controlled by
joystick. No details were given about diagnostic cri-
teria used. There was no control task. Training was
completed three times a week over 12 weeks. Results
showed that neuropsychology scores over a 28-week
period following treatment and subjective improve-
ment. There was no specific data on acceptability.
Micarelli et al. [42]
This case control study examined the effect of a
VR racing game, steered via head movement, on
vestibular rehabilitation. Participants with unilateral
vestibular hypoactivity (UVH, n = 47) comprising
older adults and MCI were further divided into treat-
ment (older adults n = 12, MCI n = 11) and control
groups (older adults and MCI n = 12). All groups
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Table 2b
Results of Treatment Studies
Study Between groups Outcome Acceptability Effect sizes Subjective Validation
differences measures measure measures
Bourellier et al.
[39]
• No difference in
age/educational
level.
• Significant
difference in
MMSE
(p < 0.001) and
TUG test
(p = 0.005).
2*2 ANOVA
Group (MCI,
Control) and
Session
(Implicit/VR
versus
Explicit/Physio)
• Session: F
(1,20)=30.70,
p < 0.001
• Group: F (1,
20)=16.47,
p < 0.001
• Interaction: F (1,
20)=6.67,
p = 0.01, MCI
subjects sig
fewer
appropriate
movements in
implicit session
(p < 0.001), no
difference in
explicit session.
Semi-structured
interview of
30 min in a quiet
room. Patients
reported
enjoying iVR
more than the
explicit
physiotherapy
session which
they found
repetitive.
Not calculated. Not assessed
quantitively,
subjects
reported
enjoying VR
tasks but some
found 3D
glasses
unwieldly and
preferred
therapist
presence
(explicit task)
Some content
validity,
construct
validity not
calculated.
White and
Moussavi. [40]
Not applicable to
case study
Average number
of navigation
errors and wall
errors both
improved over
time (R2 0.463
and 0.458,
respectively),
MoCA scores
stable (23-26
over 28-week
period). No
other statistics
calculated.
Subjective
reduction in
self-deprecating
comments, no
other data
reported.
Not applicable Patient and his
wife reported
more confidence
driving and
improved mood
Not used.
Optale et al. [41] Not applicable to
case study
No statistics
calculated. Neu-
ropsychology
measures stable
over 28-week
period. No
changes
reported in
serial EEG, CT,
MRI, laboratory
tests (no further
data on which
tests or
interval).
No specific data. Not applicable Patient reports
improvements
in word finding,
sleep.
Not used.
(Continued)
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Table 2b
(Continued)
Study Between groups Outcome Acceptability Effect sizes Subjective Validation
differences measures measure measures
Micarelli et al.
[42]
Lower mean
MMSE for MCI
versus controls
(25.8 versus
28). Age,
gender,
educational
level noted but
not formally
compared
VOR MCI HMD
versus Control
(p = 0.0008),
Otoneurological
measures Power
Spectra low
frequency (most
affected by
vestibular
issues) effect
sizes eyes
closed: 0.34,
0.27, eyes open
1.14, 0.97
Positive
correlation
between MMSE
& pre-post
differences in
low frequency
power spectra
(r-0.72) and
DGI (r = 0.76)
Not measured
directly.
Subjective
measures of
nausea and
disorientation
were reduced in
the treatment
group over time
and compared
to controls.
Not calculated: Cohens d
calculated for
MCI HMD
versus control
Dizziness
Handicap
Inventory 1.78,
DGI 0.29, ABC
0.25
Nothing formal,
construct and
face validity
evident.
ABC, Activities-specific Balance Confidence Scale; ANOVA, analysis of variance; CT, computerized tomography; DGI, Dynamic Gait
Index; EEG, electroencephalogram; HMD, head mounted display; iVR, Immersive virtual reality; TUG, timed up and go task; VOR,
vestibulo-ocular reflex. See Table 2a for remaining abbreviations.
received the same vestibular rehabilitation program
for 40 min daily but the treatment group addition-
ally spent 20 min per day playing the VR racing
game. Participants in the treatment condition (includ-
ing those with MCI) exhibited greater improvement
in vestibular function than those in the non-treatment
condition. There was no alternative treatment to VR
for the control group which led to a high risk of perfor-
mance bias. Acceptability was not measured directly
but subjective measures of nausea and disorientation
were reduced in the treatment group compared to
controls.
DISCUSSION
The breadth of studies included in this review
demonstrate the rich opportunity available to
researchers by iVR technology. These range from
simulating IADLs such as catching a bus and cash
machine withdrawals [37], to balance retraining [42]
and assessment of AD-specific navigation deficits
[34]. iVR offers distinct advantages for research
and therapy reliant on movement and engagement
in physical space. Where they were asked, patient
groups reported enjoying iVR and this may contribute
to therapeutic advantage [39, 42]. iVR also has the
potential advantage of rich and meaningful outcome
measures such as IADLs and navigation.
iVR equipment continues to improve and become
more affordable. Several of the studies included use
off the shelf commercial iVR equipment [36, 42]. Ear-
lier acceptability concerns around motion sickness
and related side effects were not problematic in any
of the studies. Even when tasks included vestibular
rehabilitation all groups tolerated iVR without inci-
dent [42]. Some studies did mention the need to adjust
equipment according to hair/visual acuity and mobil-
ity [37, 42]. This must be considered with any future
technology developments if these are to be used with
older people. Other potential limiting factors on the
clinical utility of iVR are the tendency of HMD equip-
ment to be relatively cumbersome and heavy, lack of
standardized programs and difficulty implementing
equipment in a healthcare setting.
iVR can be used to discriminate people with AD
from controls/other dementia processes
Howett et al. [34] designed a navigation task to test
the function of the entorhinal cortex. This task dif-
ferentiated participants with biomarker positive MCI
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from those with biomarker negative MCI and con-
trols. The task was critically dependent on iVR. The
integration of multisensory cues generated through
physical movement and head rotation was pivotal to
the success of this task. Other studies were able to
discriminate participants from controls but used com-
plex tasks which were not hypothesis driven. In these
studies, it is difficult to determine whether iVR or
other aspects of the tasks were important. For exam-
ple, the two tasks studied by Seo et al. [37] were
very well suited to iVR and all participants were
able to interact in a meaningful way with the vir-
tual environment (boarding the correct bus or use a
cash machine with a specific pin code). Spatial and
episodic memory-based elements of the task were not
separately measured. As a result, it is unclear which
aspects of the task discriminated participants with AD
from controls.
Similar issues affected other studies where iVR
tasks were designed as proofs of concept [35, 36, 38].
This led to tasks not being assessed as independent
screening measures [38] or the use of iVR simply
making tasks more confusing for patient participants
[35]. Gago et al. used the same task to distinguish
participants with AD [36] and Parkinson’s disease
[43] from controls. This measure was well tolerated
by participants but may simply select out any patient
at high risk of falls. The common problem for these
studies was lack of focus in the design on AD-specific
neuropathology. To aid the diagnosis and treatment
of AD, iVR tasks should adopt a hypothesis driven
approach targeting specific cognitive processes that
are dependent upon neuroanatomical structures com-
promised in early AD pathology.
There is limited evidence that iVR can to contribute
to improvements in real-world function
Despite lack of significant therapeutic benefit,
participants with AD and MCI reported enjoying
treatment tasks. These ranged from fruit picking as
an alternative to standard physiotherapy [39] to car
racing for vestibular rehabilitation [42] and simu-
lated navigation tasks [40, 41]. Increased engagement
should be considered a positive factor in design-
ing training system for participants with cognitive
deficits. On some tasks, overall performance and
learning were also improved compared to controls
tasks [42]. This suggests that iVR has the potential
to engage vulnerable groups meaningful in rehabil-
itation tasks which are otherwise very difficult to
sustain.
There was a lack of longitudinal studies. Case stud-
ies focused on cognitive training in AD [40, 41] noted
high patient engagement and subjective benefit for
the participants with cognitive measures remaining
stable over a significant period (28 weeks for both)
and improved performance shown on a spatial cogni-
tion task [40]. It will be important to complete larger
longitudinal studies to address longer term response
to treatment. Methodological issues which should
be anticipated include ensuring consistent supervi-
sion of iVR sessions and measures to reduce risk of
attrition/assess reasons for this which might relate to
tolerability.
Strengths
The present review is the first to focus specifically
on iVR in AD. We have developed clear inclusion and
exclusion criteria not utilized in previous work [21].
This makes our definitions of technology reliable
and reproducible. We used a rigorous and systematic
search strategy which was supported by a specialist
research librarian (IK). This leads to very low risk of
missing relevant studies or reviews. Our authors are
from clinical and clinical research backgrounds. As a
result, we are able to offer a meaningful appraisal
of the uses and challenges of iVR in real clinical
practice.
Limitations
The search strategy for the current review only
searched major databases. Any non-academic/games
industry/grey literature sources will have been omit-
ted. This is a very new and rapidly developing area
of research and it is possible that new terms/journals
and technologies will have developed which are not
indexed by major databases.
We were unable to answer more detailed questions
around the evidence base for iVR in AD treatment
due to sparsity of evidence. Small studies and variable
outcome measures suggest a field in its infancy and
limit the generalizability of conclusions. These issues
also preclude the meaningful use of meta-analysis
and increases the risk of bias.
Focus for future research
Future tasks implemented in iVR should target
cognitive tasks known to be affected by neu-
rodegenerative processes. Association of biomarker
positive MCI with navigation deficits [34] suggests
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several outstanding research questions. Firstly, do
participants identified at high risk of AD actually
progress to AD diagnoses? Secondly, do participants
with positive AD biomarkers but without cognitive
deficits demonstrate navigation deficits specific to the
entorhinal cortex? If deficits are noted, this offers the
potential for identifying targets for therapy at ear-
lier stages than currently possible. It may also be
feasible to complete functional imaging during task
performance [44] allowing more direct comparison
with animal models. Indeed, there is already a lit-
erature emerging in which human and animal iVR
performance is compared in this manner which may
contribute to increased power to distinguish useful
new drug treatments at an animal stage of trials [45].
By linking iVR training studies to existing clinical
cohorts it will be possible to determine much more
precisely if these techniques have additional bene-
fit beyond conventional measures. The PROTECT
program has already demonstrated that practice on
abstract reasoning tasks can lead to differential
improvement in overall cognitive function for older
participants [46]. These generalized effects appear
stronger in individuals with cognitive impairment and
we might therefore expect iVR spatial navigation
training to have particular benefits for less mobile
elderly people with MCI/AD who suffer impair-
ments both in their physical ability to mobilize and
the cognitive systems which control these processes.
Additional benefit could also be seen from errorless
learning and empowerment techniques [47].
An ethical concern around the use of iVR in
AD is whether users may become confused about
whether they are inhabiting the real or a virtual
world. This may present a challenge to any users
given sufficiently sophisticated technology. People
with dementia would be expected to be at earlier risk.
This could potentially lead to increased distress or
even, conversely, reluctance to leave pleasant or safe
therapeutic iVR environments for the confusion and
stress of reality. There is little evidence yet in the
field of these tensions. Reasons why participants were
unable to participate in studies should be explored
in greater detail [35]. Limited duration of iVR use
and rigorous testing of software on cognitively intact
participants before use in patient groups will help.
Clear standards over the therapeutic focus of tech-
nology will also reduce risk, but this is an area in
need of regular review as opportunities within the
field expand.
As experience with iVR develops, it may become
possible to augment specific memories or skills in the
real world through simulated practice. This could be
in a similar manner to Occupational Therapy (OT)
practice in a hospital kitchen. OT sessions clarify
deficits and helps with function when the patient
returns home. Already this area is being explored
with retraining cooking skills in iVR [48, 49]. Aug-
mented and mixed reality technology will allow more
seamless integration. We may be also able to tailor
systems to individual users’ impairments by inte-
grating familiar people/places into virtual worlds to
reduce cognitive stress and reducing risk of behav-
ioral and psychological symptoms of dementia in
a similar manner to shared reminiscence therapy
[50]. Early work shows such treatment is toler-
ated by participants but benefits are not yet clear
[26].
Other preliminary research suggests residential
home residents with dementia reported enjoying
shared iVR sessions and that these also reduced
apathy [51]. Further controlled trials are underway.
Finally, it is also feasible to imagine iVR being used
for assessment of high-risk tasks such as driving [52]
and to help maintain interest in spatial activities when
driving is no longer safe.
Summary
This systematic review shows the field of iVR
for the assessment and treatment of AD is starting
to step out its infancy. Participants found iVR tasks
demanding but were able to participate and reported
enjoying the tasks and interfaces [35, 39]. The intu-
itive nature of the technology makes it very appealing
even to those with a significant burden of disease.
Incorporating measures of spatial cognition within
iVR assessment has already demonstrated remark-
able discriminative potential for detecting preclinical
AD [34].
It is less clear whether iVR can offer any specific
cognitive benefits, but potential has been demon-
strated to use iVR to facilitate broader physical and
vestibular rehabilitation [39, 42]. As patients with AD
often find it difficult to engage with repetitive activ-
ities as part of physical therapy, it is useful to note
that iVR can facilitate such treatment. It is impor-
tant to ensure that future use of this technology is
theoretically grounded and controlled to avoid poten-
tial harm to vulnerable patient groups. Collaboration
between clinical researchers and software engineer-
ing teams is crucial to build on the early potential
demonstrated.
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